{"filings":[{"id":650237,"accession_number":"0001193125-26-238059","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2026-05-26T12:56:06+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Corbus reports CRB-701 42.9% cORR in 2L OPSCC at 3.6 mg/kg; registrational study planned summer 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["cORR 42.9% (9/21) in 2L OPSCC at 3.6 mg/kg; median DOR 6.3 mo, PFS 5.6 mo.","cORR 34.4% (11/32) in 2L cervical cancer at 3.6 mg/kg; 2 complete responses, DOR 8.0 mo.","Safety: treatment discontinuations 2.8%; no Grade 5 events; ocular AEs manageable.","FDA alignment on registrational trials: TEMPO-1 (OPSCC, n=250) to start summer 2026.","85.4% of OPSCC patients HPV+; 8 of 9 responders in OPSCC were HPV+."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":564198,"accession_number":"0001193125-26-233507","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2026-05-21T12:15:15+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Corbus appoints Nishant Saxena as first Chief Business Officer; schedules CRB-701 data call","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nishant Saxena appointed CBO; base salary $470K, 192,300 options and 58,300 RSUs as initial equity.","Conference call on May 26 at 8:00 a.m. EDT to discuss updated Phase 1/2 CRB-701 data (data cut April 1).","Upcoming milestones: initiation of registrational study of CRB-701 in second-line HNSCC and completion of CANYON-1 Phase 1b for CRB-913 (CB1 inverse agonist).","Brent Pfeiffenberger granted 24,700 nonqualified options and 7,500 RSUs as initial board equity awards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":78042,"accession_number":"0001193125-26-222890","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2026-05-14T12:15:14+00:00","items":["5.02","5.07","7.01","9.01"],"status":"ready","headline":"Corbus appoints Brent Pfeiffenberger to board; shareholders approve 3M share increase for equity plan","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Brent Pfeiffenberger (CEO Century Therapeutics, former SVP BMS) to board, expanding to 7 members.","Stockholders approved amendment to 2024 Equity Plan increasing authorized shares by 3M to total 5M shares.","All six director nominees elected; advisory say-on-pay approved with 92% of votes cast in favor.","CRB-701 Nectin-4 ADC data at ASCO 2026; FDA alignment on registration path for HNSCC; registrational study this summer.","CANYON-1 Phase 1b study for CRB-913 (CB1 inverse agonist) on track to complete summer 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":22846,"accession_number":"0001193125-26-218250","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2026-05-12T12:15:16+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corbus Q1 net loss $23M, cash $138.2M; FDA alignment for CRB-701 registration path","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $23.0M ($1.23 diluted LPS) vs $17.0M loss ($1.39 LPS) in Q1 2025.","Cash and investments $138.2M as of March 31, 2026, expected to fund operations into 2028.","Reached broad FDA alignment on registration path for CRB-701 in 2L HNSCC and cervical cancer; registrational study start expected summer 2026.","Updated CRB-701 data to be presented at ASCO 2026; CANYON-1 obesity study (n=240) fully enrolled, topline data summer 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93953,"accession_number":"0001193125-26-159062","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Corbus Pharma amends employment agreements: CEO salary $673,625, CFO salary $501,273","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New employment agreements for CEO Yuval Cohen and CFO Sean Moran, effective April 15, 2026.","CEO Cohen: base salary $673,625, bonus target up to 60%, term through April 15, 2028.","CFO Moran: base salary $501,273, bonus target up to 40%, term through April 15, 2028.","CEO severance: 12 months' base salary, COBRA; change-in-control: 24 months, 2x bonus, full vesting.","CFO severance: 12 months' base salary, COBRA; change-in-control: 18 months, 1x bonus, full vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93952,"accession_number":"0001193125-26-153923","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Corbus completes enrollment in CANYON-1 Phase 1b trial of CRB-913 for obesity; on track for summer 2026 data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Last patient enrolled and completed first visit in CANYON-1 Phase 1b trial of CRB-913, a peripherally restricted oral CB1 inverse agonist.","Trial is a 16-week, placebo-controlled, dose-ranging study (n=240) with 20, 40, and 60 mg QD cohorts; completion expected summer 2026.","Phase 1a data showed 2.9% placebo-adjusted weight loss at Day 14 in obese cohort, with no vomiting, constipation, or nausea reported.","Neuropsychiatric assessments (CSSRS, PHQ-9, GAD-7) were negative across all cohorts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93951,"accession_number":"0001193125-26-144588","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"Corbus Pharma announces FDA alignment for CRB-701 accelerated path; CMO resigns","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA agreed on registrational study designs for CRB-701 in second-line HNSCC and cervical cancer, with potential accelerated approval using ORR primary endpoint.","Dr. Dominic Smethurst steps down as Chief Medical Officer, effective June 30, 2026.","Updated CRB-701 monotherapy data accepted for presentation at ASCO 2026 (May 29-June 2).","Company expects to report CRB-701 + Keytruda data in first-line HNSCC in Q4 2026; registrational study for HNSCC to start mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105979,"accession_number":"0001193125-26-097582","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corbus Q4 net loss $20.6M; cash $163.3M into 2028; key CRB-701/913 catalysts mid-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net loss $20.6M ($1.25/share) vs $9.5M ($0.78) in Q4 2024; operating expenses rose to $22.0M.","Cash $163.3M at Dec 31, 2025; extended runway into 2028 after $75M public offering in Q4.","CRB-701 Phase 1/2 unconfirmed ORR: HNSCC 47.6%, cervical 37.5%; monotherapy data and FDA protocol discussions expected mid-2026.","CRB-913 Phase 1a: 2.9% placebo-adjusted weight loss at 14 days; Phase 1b CANYON-1 (n=240) results due summer 2026.","CRB-601 deprioritized; no further patient enrollment. Pipeline updates from ESMO 2025 and SITC 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105978,"accession_number":"0001193125-26-068566","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Corbus Pharmaceuticals updates investor presentation; no specifics extractable from truncated exhibit","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corbus Pharmaceuticals Holdings updated its corporate investor presentation on February 25, 2026.","The presentation excerpt provided in the filing is incomplete; full content is not available.","No new financial guidance, pipeline milestones, or strategic changes can be identified.","The update appears to be a routine refresh of corporate materials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105977,"accession_number":"0001193125-26-009758","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Corbus updates investor presentation; no new material financial or operational data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Furnished updated corporate presentation under Item 7.01 Regulation FD.","Presentation dated January 12, 2026; no specific changes or metrics provided in filing.","No earnings, guidance, or clinical milestones reported in the exhibit text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122259,"accession_number":"0001193125-25-324796","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Alan Holmer resigns from Corbus board effective Dec 31, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alan Holmer notified Corbus of his resignation from the Board on Dec 12, 2025, effective Dec 31, 2025, citing retirement.","His resignation is not due to any disagreement with the Company or its management on operations, policies or practices.","No replacement director has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122258,"accession_number":"0001193125-25-315039","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Corbus posts Phase 1a data for CRB-913: weight loss signal, no serious AEs; Phase 1b started","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1a SAD/MAD of oral CB1 inverse agonist CRB-913 (n=112) showed no serious AEs, no GI intolerability, no neuropsychiatric events except mild anxiety/irritability in obese cohort.","In obese MAD cohort (150 mg QD), all 9 CRB-913-treated participants lost weight; mean placebo-adjusted 2.9% loss at Day 14 (range 1.3-4.3%).","Initiated Phase 1b CANYON-1 (12-week, 240 obese non-diabetic participants, doses 20/40/60 mg); completion expected summer 2026.","PK profile supports once-daily dosing; no suicidality, depression, or insomnia reported across all study cohorts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122257,"accession_number":"0001193125-25-276062","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corbus Q3 net loss $23.3M ($1.90/sh); cash $104M; CRB-701 ORR 47.6% in HNSCC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $23.3M ($1.90 diluted EPS) vs $13.8M ($1.15) in Q3 2024; operating expenses up $8.9M.","Cash, equivalents $104M at Sep 30; raised $73.8M net in Oct-Nov offering extending runway into 2028.","CRB-701 ESMO data: ORR 47.6% (HNSCC), 37.5% (cervical), 55.6% (mUC) at 3.6 mg/kg; registrational study planned mid-2026.","CRB-913 SAD/MAD study on track; Ph1b in obese patients to start Q4 2025.","CRB-601 Phase 1 dose escalation ongoing; first participant dosed Dec 2024."],"consensus_eps_estimate":-1.7414,"consensus_eps_actual":-4.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122256,"accession_number":"0001193125-25-261722","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Corbus Pharmaceuticals prices $75M public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 4,744,231 shares at $13.00/share and 1,025,000 pre-funded warrants at $12.9999 each for ~$75M gross proceeds.","Net proceeds to Corbus expected ~$70.5M; underwriters have 30-day option for additional 865,384 shares.","Proceeds to fund clinical pipeline development and general corporate purposes.","Pre-funded warrants exercisable immediately at $0.0001/share, capped at 9.99% beneficial ownership.","Jefferies leads underwriting; RBC, LifeSci Capital, Mizuho as lead managers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122255,"accession_number":"0001193125-25-258692","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Corbus reports preliminary Q3 cash position of $104M as of Sep 30, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Expected cash, cash equivalents, and investments of approximately $104.0 million.","Includes $27.0 million in cash and cash equivalents.","Figures are preliminary, subject to final closing procedures.","No update on sales under Jefferies ATM agreement after September 30."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122254,"accession_number":"0001193125-25-243046","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Corbus Pharma reports CRB-701 Phase 1/2 ORR 47.6% HNSCC, 55.6% mUC at ESMO25","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["3.6 mg/kg dose: ORR 47.6% in HNSCC (n=21), 37.5% in cervical cancer (n=16), 55.6% in mUC (n=9).","No grade 4/5 treatment-related AEs; low discontinuation rate (6.0%) and peripheral neuropathy (8.4% Grade 1/2).","Responses seen regardless of Nectin-4, HPV, or PD-L1 status; median prior therapies = 3.","Company plans FDA meeting in 2025 and registrational studies by mid-2026.","Data presented at ESMO25 from 167 patients; 122 evaluable for efficacy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138966,"accession_number":"0001193125-25-204389","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2025-09-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA grants Fast Track designation for Corbus' CRB-701 in recurrent/metastatic HNSCC","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Fast Track for CRB-701 to treat HNSCC after prior platinum and anti-PD(L)-1 therapy.","Second Fast Track designation for CRB-701; first was for cervical cancer in December 2024.","Phase 1/2 dose optimization data to be presented at ESMO 2025 on October 19, 2025.","CRB-701 is a next-generation Nectin-4 targeting ADC with site-specific cleavable linker and MMAE payload (DAR 2).","Ongoing Phase 1/2 trial evaluating safety, PK, and efficacy in advanced solid tumors with high Nectin-4 expression."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138965,"accession_number":"0000950170-25-102447","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corbus Pharmaceuticals Q2 2025 Net Loss $17.7M, Pipeline on Track for Data Readouts H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q2 2025 was $17.7 million ($1.44 per share), compared to $10.0 million loss in Q2 2024.","Cash and investments totaled $116.6 million as of June 30, 2025, expected to fund operations through Q2 2027.","Phase 1/2 dose expansion data for Nectin-4 ADC CRB-701 to be presented at ESMO 2025 in October.","Obesity drug CRB-913 initiated multiple ascending dose portion; SAD/MAD data expected later in 2025.","FDA granted Fast Track designation for CRB-701 in relapsed/refractory metastatic cervical cancer."],"consensus_eps_estimate":-1.5422,"consensus_eps_actual":-2.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156450,"accession_number":"0000950170-25-073967","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Corbus Pharma shareholders elect directors, ratify auditor, approve say-on-pay; Rachelle Jacques appointed Board Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["All seven director nominees elected (Yuval Cohen, Alan Holmer, Rachelle Jacques, John Jenkins, Anne Altmeyer, Yong Ben, Winston Kung; broker non-votes 2,281,655).","Ratification of EisnerAmper LLP as independent auditor for FY2025 approved: 8,841,947 for, 154,305 against, 32,193 abstain.","Advisory vote on named executive officer compensation passed: 6,519,904 for, 215,784 against, 11,102 abstain, 2,281,655 broker non-votes.","Board appoints Rachelle Jacques as Chair, effective immediately, succeeding Alan Holmer who remains on board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156449,"accession_number":"0000950170-25-063990","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corbus Pharma Q1 net loss $17M; pipeline on track for data in H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $17.0M ($1.39/share) vs $6.9M ($0.83) in Q1 2024; operating expenses rose to $19.8M.","Cash and investments $132.8M; expected to fund operations through Q2 2027.","CRB-701 Nectin-4 ADC dose optimization ongoing; RP2D expected Q4 2025; FDA Fast Track for cervical cancer.","CRB-913 CB1 inverse agonist Phase 1 SAD/MAD started March 2025; completion Q3 2025; Phase 1b starts Q4 2025.","CRB-601 anti-αvβ8 mAb Phase 1 dose escalation ongoing; completion expected Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174888,"accession_number":"0000950170-25-043276","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2025-03-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Peter Salzmann not standing for re-election; board size reduced to seven","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Salzmann will not stand for re-election at the 2025 annual meeting.","He continues as director and Nominating and Governance Committee member until the meeting.","Decision was not due to any disagreement with the company.","Board size reduced from eight to seven effective after the annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174887,"accession_number":"0000950170-25-041254","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Corbus appoints Ian Hodgson as COO effective March 15, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ian Hodgson, 52, previously Head of Operations, named COO effective March 15, 2025.","Annual base salary of £327,869; eligible for annual bonus up to 40% of base salary.","Employment subject to 3-month notice period; non-compete for 3 months, non-solicit for 6 months post-termination.","Dr. Hodgson holds a PhD in Medical Microbiology, over 25 years experience in drug development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174886,"accession_number":"0000950170-25-036838","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corbus reports Q4 net loss $9.5M, cash $149.1M; pipeline updates on CRB-701, CRB-913, CRB-601","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2024 $9.5M ($0.78/share) vs $8.0M ($1.81/share) in Q4 2023; full-year loss $40.2M ($3.68/share).","Cash and investments $149.1M at Dec 31, 2024; expected to fund operations through Q3 2027.","CRB-701 (Nectin-4 ADC) Phase 1 shows safety and responses in HNSCC, cervical, and mUC; FDA Fast Track for metastatic cervical cancer.","CRB-913 obesity Ph1 SAD/MAD first dosing expected March 2025; CRB-601 first patient dosed Dec 2024, dose escalation Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174885,"accession_number":"0000950170-25-020424","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Corbus CRB-701 Phase 1 Western data: low neuropathy, HNSCC responses, dose optimization started","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["No DLTs; peripheral neuropathy 5% (Grade 1-2) vs 3% in China; combined 4% across 75 patients.","Ocular AEs lower in Western study (38% vs 66%) with proactive prevention protocol at 2.7/3.6 mg/kg.","Efficacy: 4 PR in HNSCC (n=7); 1 CR in cervical; mUC responses despite prior EV treatment.","PK comparable to China; CRB-701 shows longer ADC half-life and lower free-MMAE vs enfortumab vedotin.","Dose optimization randomized at 2.7 and 3.6 mg/kg Q3W in HNSCC, cervical, and mUC cohorts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191837,"accession_number":"0000950170-24-132458","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA grants Fast Track designation to Corbus' CRB-701 for cervical cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CRB-701 is a next-generation Nectin-4 ADC with site-specific cleavable linker, MMAE payload, DAR 2.","Company completed dose-escalation enrollment for Phase 1 trial in US/Europe (NCT06265727).","First clinical data from dose-escalation study expected in Q1 2025.","Fast Track designation aims to speed development and review for unmet medical need in metastatic cervical cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191836,"accession_number":"0000950170-24-127644","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Board member Anne Altmeyer adopts 10b5-1 plan to sell up to 2,452 shares of CRBP common stock","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Anne Altmeyer, Ph.D., board member, adopted Rule 10b5-1 plan on Nov 14, 2024.","Plan allows sale of up to 2,452 shares of common stock.","Sales may begin on February 13, 2025; plan terminates December 31, 2025.","Plan is intended to satisfy affirmative defense under Rule 10b5-1(c)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191835,"accession_number":"0000950170-24-122839","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corbus Q3 net loss $13.8M; CRB-701 dose escalation complete; cash $159.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.8M ($1.15/diluted share) vs $10.1M ($2.27) in Q3 2023; operating expenses up $6.0M to $15.5M.","Cash, cash equivalents and investments $159.4M; expects to fund operations through Q3 2027.","Raised $35.6M net proceeds via ATM program in Q3 by issuing 663,730 shares.","Completed enrollment in CRB-701 dose escalation part of Phase 1; first data expected in Q1 2025.","Final $11.8M loan payment made; loan fully paid off."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191834,"accession_number":"0000950170-24-120289","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Corbus presents pre-clinical data for obesity drug CRB-913; Phase 1 start Q1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CRB-913 showed 15-fold lower brain levels vs monlunabant in mice; plasma-to-brain ratio 10x better than monlunabant.","Weight loss up to 38% in DIO mice at 80 mg/kg/day over 28 days; no plateau at doses up to 80 mg/kg/day.","Switching from semaglutide to CRB-913 maintained weight loss post-withdrawal, with doubling of fat reduction vs semaglutide alone.","Human-equivalent doses range from 30 mg/day to 450 mg/day based on allometric scaling.","IND-enabling studies ongoing; first patient in Phase 1 expected in Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208320,"accession_number":"0000950170-24-102878","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Director John Jenkins adopts 10b5-1 plan to sell up to 5,436 CRBP shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plan covers up to 5,436 shares of common stock, effective November 30, 2024.","Plan terminates on November 29, 2025, per Rule 10b5-1(c) affirmative defense.","Dr. Jenkins is a member of the board of directors of Corbus Pharmaceuticals.","Trading plan adopted on August 29, 2024; sales may begin after the 90-day cooling-off period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208319,"accession_number":"0000950170-24-098861","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2024-08-20T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Corbus Pharmaceuticals appoints Winston Kung to Board, replaces exiting director Chip Catlin","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Avery 'Chip' Catlin resigned from Board and as Audit Chair effective Aug 15, 2024; no disagreement with company.","Winston W. Kung, age 49, appointed to Board effective Aug 16, 2024; will serve as Audit Committee Chair.","Kung is CFO of ArriVent BioPharma; previously COO/CFO at PMV Pharma, VP at Celgene, and roles at Citigroup and Lehman.","Kung receives initial option grant for 5,566 shares and 5,566 RSUs; annual cash retainer $40,000 plus $20,000 for Audit Chair."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208318,"accession_number":"0000950170-24-091931","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Corbus files updated corporate presentation; no substantive news identified","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Corbus Pharmaceuticals furnished an updated corporate investor presentation on August 6, 2024.","The filing excerpt does not reveal any specific financial, clinical, or strategic updates.","The presentation title includes 'Connecting Innovation to Purpose' with no further details provided.","Given the limited content available, no material new information for investors can be derived."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208317,"accession_number":"0000950170-24-091219","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corbus Pharma Q2 loss $10M; CRB-701 shows 44% ORR in mUC; cash runway through Q3 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.0M ($0.90 per diluted share) for Q2 2024, compared to net loss of $8.8M ($2.05 per share) in Q2 2023.","Cash and investments of $147M at June 30; raised $28.8M additional through Aug 1; cash runway extended through Q3 2027.","CRB-701 Phase 1 data: 44% ORR and 78% DCR in metastatic urothelial cancer; 43% ORR and 86% DCR in cervical cancer at doses ≥1.2mg/kg.","US/EU Phase 1 dose escalation for CRB-701 commenced April 2024; completion expected Q4 2024; data presentation Q1 2025.","CRB-913 Phase 1 start expected Q1 2025; CRB-601 Phase 1 start expected Q4 2024; both pre-clinical data support advancement."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225945,"accession_number":"0000950170-24-074032","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Corbus board member Dr. Yong Ben adopts 10b5-1 plan for up to 10,607 shares","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Dr. Yong Ben, a board member, adopted a Rule 10b5-1 trading plan on June 14, 2024.","Plan authorizes sale of up to 10,607 shares of CRBP common stock.","Sales may begin September 12, 2024; plan terminates September 11, 2025.","Plan is intended to satisfy affirmative defense under Rule 10b5-1(c)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225944,"accession_number":"0000950170-24-067651","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Corbus reports Phase 1 data for CRB-701 at ASCO: 44% ORR in mUC, 43% in cervical cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["44% ORR and 78% DCR in mUC (n=9), 43% ORR and 86% DCR in cervical cancer (n=7) at doses ≥1.2 mg/Kg.","No DLTs or grade 4/5 AEs observed to date; single grade 1 neuropathy (resolved) and 3 skin rashes (resolved).","Free MMAE levels lower than enfortumab vedotin across all doses up to 4.5 mg/Kg.","Enrollment expanded to 37 patients (25 evaluable); US phase 1 completing Q4 2024, data Q1 2025.","Preventative eye measures introduced after two grade 3 corneal disorders; no further cases at 4.5 mg/Kg."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225943,"accession_number":"0000950170-24-062436","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Corbus stockholders approve 2024 Equity Compensation Plan reserving 2M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved 2024 Equity Compensation Plan, reserving 2,000,000 shares of common stock for issuance under options, SARs, restricted stock, RSUs, and performance awards.","All eight director nominees (Yuval Cohen, Alan Holmer, Avery Catlin, Rachelle Jacques, John Jenkins, Peter Salzmann, Anne Altmeyer, Yong Ben) were elected with at least 6.19M votes for each.","Ratification of EisnerAmper LLP as independent auditor for fiscal 2024 approved with 8,388,012 votes for.","Advisory vote on executive compensation passed with 6,593,949 votes for, 44,363 against, and 1,962,726 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225942,"accession_number":"0000950170-24-056291","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Corbus updates risk factors; no new operational or financial events","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing supplements risk factors for Q1 2024; no change in business outlook.","Highlights dependence on contract manufacturers and CROs for clinical supply.","Notes exposure to U.S.-China trade policies and proposed BIOSECURE bill through CSPC license.","Repeats standard IP infringement litigation risks; no suits filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225941,"accession_number":"0000950170-24-053978","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corbus Q1 net loss narrows to $6.9M; raised $116M, cash runway through Q1 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.9M ($0.83/diluted share) vs $17.7M ($4.24) in Q1 2023, driven by lower operating expenses.","Raised $116M in Q1 via public offering ($94.5M) and ATM ($21.1M); cash, equivalents & investments $120.1M.","Phase 1 data for CRB-701 (next-gen Nectin-4 ADC) to be presented at ASCO 2024 on June 1, 2024.","Appointed Dr. Dominic Smethurst as Chief Medical Officer; expects first CRB-913 patient dosed in Q1 2025.","IND cleared for CRB-601 (anti-αvβ8 mAb); Phase 1 initiation expected summer 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225940,"accession_number":"0000950170-24-043417","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2024-04-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Corbus enters amended employment agreements with CEO and CFO; base salaries $622,804 and $463,455","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Yuval Cohen's 2-year agreement: base salary $622,804, bonus target up to 60% of base.","CFO Sean Moran's 2-year agreement: base salary $463,455, bonus target up to 40% of base.","Change-in-control severance: CEO 24 months salary, CFO 18 months; plus accelerated equity vesting.","Non-compete (6 months) and non-solicitation (12 months) apply, conditional on severance.","Agreements expire April 10, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245046,"accession_number":"0000950170-24-034271","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2024-03-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CEO and CFO adopt Rule 10b5-1 trading plans for up to 159,672 shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Yuval Cohen plan: sale of up to 117,066 shares beginning June 13, 2024, ending March 15, 2025.","CFO Sean Moran plan: sale of up to 42,606 shares, same start and termination dates.","Both plans adopted March 15, 2024, disclosed via 8-K on March 20, 2024.","Plans intended to satisfy affirmative defense of Rule 10b5-1(c)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245045,"accession_number":"0000950170-24-029667","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corbus Pharma reports Q4 net loss $8.0M; cash $127M after $116M raise; CRB-701 shows 43% ORR","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 $8.0M ($1.81/diluted) vs $10.9M ($2.61) YoY; full year loss $44.6M ($10.31).","Cash, equivalents & investments $127M as of Feb 2, 2024 after $116M capital raise; runway 3+ years through Q1 2027.","CRB-701 (Nectin-4 ADC) Ph1 data: 43% ORR, 71% DCR at >=2.7 mg/kg; no DLTs, neuropathy, or skin rash. US Ph1 patient dosing starts March 2024.","FDA cleared IND for CRB-601 (TGFβ blocker); Ph1 start summer 2024. CRB-913 (CB1 inverse agonist) IND filing on track for Q4 2024.","Appointed Dr. Dominic Smethurst as CMO, previously CMO of Bicycle Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245044,"accession_number":"0000950170-24-011733","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2024-02-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Corbus Pharmaceuticals CSO Rachael Brake resigns effective Feb 19, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chief Scientific Officer Rachael Brake submitted resignation on Feb 2, 2024.","Resignation effective February 19, 2024.","No replacement or reason for departure disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245043,"accession_number":"0000950170-24-011013","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2024-02-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Corbus Pharmaceuticals updates investor presentation; no material changes disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed updated corporate presentation dated February 2, 2024, as Exhibit 99.1.","Presentation title slide only provided; no specific operational or financial updates included.","No new drug pipeline milestones, financial results, or strategic changes announced.","Routine disclosure under Regulation FD; presentation available on company website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245037,"accession_number":"0000950170-24-009973","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K/A","filed_at":"2024-02-02T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Corbus Pharmaceuticals files non-substantive 8-K/A to correct Exhibit 5.1 signature","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment corrects omitted conformed signature on Lowenstein Sandler LLP legal opinion filed as Exhibit 5.1.","Original 8-K filed Feb 1, 2024 remains unchanged; no new financial or business disclosures.","Underwriting agreement and two press releases from Jan 30-31, 2024 are incorporated by reference unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245042,"accession_number":"0000950170-24-009874","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2024-02-01T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Corbus Pharmaceuticals prices public offering of 4.325M shares at $19, expects ~$88.5M net proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 4,325,000 shares of common stock at $19.00 per share; underwriters' option for additional 648,750 shares exercised in full.","Net proceeds expected to be approximately $88.5 million after underwriting discounts and estimated offering expenses.","Offering expected to close on or about February 2, 2024; proceeds to fund clinical pipeline development and working capital.","Jefferies acted as sole book-runner; H.C. Wainwright & Co. and Oppenheimer & Co. as lead managers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245041,"accession_number":"0000950170-24-009086","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2024-01-31T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Corbus suspends ATM equity offering program, terminates Jan 29 prospectus supplement","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Suspended and terminated the ATM prospectus supplement dated Jan 29, 2024, under Sale Agreement with Jefferies.","No sales of common stock until a new prospectus supplement is filed.","The underlying Sale Agreement dated August 6, 2020, remains in full force and effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245040,"accession_number":"0000950170-24-008129","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2024-01-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Corbus reports preliminary cash of $20.9M as of Dec 31, 2023; raised $16.8M via ATM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised approximately $16.8M in gross proceeds from common stock sales under Open Market Sale Agreement with Jefferies.","Preliminary cash, cash equivalents, and investments of ~$20.9M as of Dec 31, 2023, including $13.7M in cash.","Financial statements for year ended Dec 31, 2023 not yet finalized; amounts subject to adjustments.","Company has not provided any revenue or earnings guidance in this update."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245039,"accession_number":"0000950170-24-007703","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2024-01-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Corbus announces Phase 1 data for CRB-701: 43% ORR at therapeutic doses, no peripheral neuropathy or skin rash","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 dose-escalation data for CRB-701 (SYS6002) in nectin-4 positive tumors presented at ASCO GU 2024.","At doses ≥2.7 mg/kg (n=7), ORR 43% (3 partial responses) and disease control rate 71%; no grade 3+ adverse events.","No dose-limiting toxicities, peripheral neuropathy, or skin rash observed; dose escalation ongoing at 4.5 mg/kg.","CRB-701 showed lower free MMAE exposure vs enfortumab vedotin; longest ongoing response ~10 months.","U.S. clinical study expected to start in Q1 2024 under already-open IND."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245038,"accession_number":"0000950170-24-003197","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["3.01","7.01","8.01","9.01"],"status":"ready","headline":"Corbus receives FDA IND clearance for CRB-601; Nasdaq grants extension to May 8, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for CRB-601, a TGFβ blocking monoclonal antibody targeting integrin αvβ8.","Phase 1 study first participant enrollment expected in H1 2024; pre-clinical data showed enhanced anti-tumor activity.","Nasdaq granted extension until May 8, 2024 to regain compliance with $2.5M stockholders' equity requirement, conditional on capital raise.","Stockholders' equity was $311,016 as of Sep 30, 2023, below the $2.5M minimum; alternative standards not met.","Failure to regain compliance by May 8, 2024 may lead to delisting; company has right to appeal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262483,"accession_number":"0000950170-23-063854","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Corbus files routine investor presentation update; no material new information","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filing includes an updated corporate slide deck dated November 2023.","No financial results, guidance changes, or pipeline updates were disclosed.","Presentation appears to be a standard refresh of company materials.","No material events or operational developments were reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262482,"accession_number":"0000950170-23-063134","cik":1595097,"company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["3.01","8.01"],"status":"ready","headline":"Corbus receives Nasdaq delisting notice for equity below $2.5M minimum","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Corbus on Nov 10, 2023 that stockholders' equity of $311,016 as of Sept 30, 2023 is below the $2.5M minimum for continued listing.","Corbus has 45 calendar days, until Dec 26, 2023, to submit a plan to regain compliance with Listing Rule 5550(b)(1).","If Nasdaq accepts the plan, it may grant an extension up to May 8, 2024; rejection can be appealed to a hearings panel.","Company also updated risk factors to warn of potential delisting consequences: reduced liquidity, penny stock rules, and impaired capital raising ability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":141181806.7672634,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-11-13T23:59:59+00:00|262482"}